Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

Prostate

Volumn 72, Issue 8, 2012, Pages 834-845

  Noguchi, Masanori ^a   Moriya, Fukuko ^a   Suekane, Shigetaka ^a   Matsuoka, Kei ^a   Arai, Gaku ^b   Matsueda, Satoko ^a   Sasada, Tetsuro ^a   Yamada, Akira ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

docetaxel; overall survival; personalized peptide vaccine; prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANCER VACCINE; DEXAMETHASONE; DOCETAXEL; INTERLEUKIN 6; MONTANIDE ISA 51; PEPTIDE VACCINE; PERSONALIZED PEPTIDE VACCINE; PREDNISONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; HYPOALBUMINEMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNITY, HUMORAL; INDIVIDUALIZED MEDICINE; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORCHIECTOMY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84860347746     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21485     Document Type: Article

References (43)

1. National Cancer Institute. Surveillance, Epidemiology and End Results.
2. Ferlay J, Parkin DM, Steliarova-Founcher E,. Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Tannock I, Osaba D, Stockler M, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC,. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764. (Pubitemid 26185452)
4. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ,. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-2513. (Pubitemid 29368252)
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1488-1490.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
7. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK,. Second-line chemotherapy for prostate cancer: Patient characteristics and survival. Clin Prostate Cancer 2005; 4: 86-90. (Pubitemid 41474602)
8. Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M, Matsuura K, Ushijima K, Maeda Y, Katagiri K, Yamada A, Todo S, Kamura T, Harada M, Itoh K,. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004; 25: 121-131.
9. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T,. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 60-72. (Pubitemid 38076169)
10. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K,. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 1001-1009.
11. Itoh K, Yamada A,. Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci 2006; 97: 970-976. (Pubitemid 44322541)
12. Itoh K, Yamada A, Mine T, Noguchi M,. Recent advances in cancer vaccines: An overview. Jpn J Clin Oncol 2009; 39: 73-80.
13. Harashima N, Tanaka K, Sasadomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Itoh K, Shichijo S,. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of metastatic cancer patients. Eur J Immunol 2001; 31: 323-332. (Pubitemid 32166585)
14. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K,. Multidrug resistance-associated protein 3 (MRP3) is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001; 61: 6459-6466. (Pubitemid 32783252)
15. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K,. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 2011; 71: 470-479.
16. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S,. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003; 57: 80-92. (Pubitemid 37070152)
17. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S,. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004; 95: 77-84. (Pubitemid 38208411)
18. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S,. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004; 60: 32-45. (Pubitemid 38669227)
19. Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K,. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63: 1-12. (Pubitemid 40365385)
20. Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M,. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007; 30: 274-281. (Pubitemid 46586643)
21. Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M,. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer 2007; 97: 1648-1654. (Pubitemid 350249351)
22. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M,. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 2007; 56: 689-698. (Pubitemid 46348730)
23. Aucouturier J, Dupuis L, Ganne V,. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19: 2666-2672. (Pubitemid 32234287)
24. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G,. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467. (Pubitemid 29517916)
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumor: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
26. Komatsu N, Shichijo S, Nakagawa M, Itoh K,. New multiplexed flow cytometric assay to measure anti-peptide antibody: A novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64: 1-11.
27. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K,. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment. Oncol Res 2007; 16: 341-349. (Pubitemid 47488078)
28. Mathew P, DiPaola R,. Taxane refractory prostate cancer. J Urol 2007; 178: S36-S41. (Pubitemid 47211164)
29. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J,. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388-1397.
30. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM,. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094. (Pubitemid 46638945)
31. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR,. Overall survival analysis of a phase II randomized control trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105.
32. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-867. (Pubitemid 36019639)
33. McArdle PA, Mir K, Almushatat AS, Underwood MA, McMillan DC,. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127-129. (Pubitemid 44195771)
34. Crumley AB, McMillan DC, McKerman M, Going JJ, Shearer CJ, Stuart RC,. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-esophageal cancer. Br J Cancer 2006; 94: 1568-1571. (Pubitemid 43924914)
35. Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR, Toogood GJ, Lodge JP,. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 2007; 96: 222-225. (Pubitemid 46160625)
36. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, Chen JH,. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007; 14: 84-93.
37. Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y, Matsudo T, Takahashi K,. Significance of serum amyloid A on the progression in patients with renal cell carcinoma. Cancer 2001; 92: 2072-2075. (Pubitemid 32973316)
38. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM,. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-1015. (Pubitemid 34017290)
39. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V,. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32: 790-802.
40. Lechner MG, Liebertz DJ, Epstein AL,. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273-2284.
41. Zou W, Restifo NP,. T(H)17cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248-256.
42. Derhovanessian E, Adams V, Hähnel K, Groeger A, Pandha H, Ward S, Pawelec G,. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009; 125: 1372-1379.
43. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J,. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-1271.